Nuvation Bio Inc. Q3 2025 Earnings Recap

NUVB Q3 2025 November 4, 2025

Get alerts when NUVB reports next quarter

Nuvation Bio reported strong momentum in its first full quarter post-IBTROZI FDA approval, with 204 new patient starts and continued positive feedback from the medical community regarding its efficacy and safety profile.

Earnings Per Share Beat

$-0.16 vs $-0.17 est.

+5.9% surprise

Revenue Miss

13120000 vs 36821810 est.

-64.4% surprise

Market Reaction

1-Day -6.58%

5-Day -8.51%

30-Day +55.51%

See NUVB alongside your other holdings

Add to your portfolio — free

Key Takeaways

IBTROZI achieved 204 new patient starts during Q3 2025, averaging over 15 per week, indicating robust market acceptance.
The median duration of response for TKI-naive patients has increased to 50 months, supporting the drug's competitive positioning as a potential new standard of care.
Recent clinical data showcased an impressive 66% intracranial response rate in patients with brain metastases, highlighting IBTROZI's unique efficacy in a critical patient subgroup.
Nuvation Bio plans to submit a supplemental NDA for a label update based on the latest data, aiming to enhance product positioning further.
The company continues to differentiate IBTROZI from competitors by emphasizing its safety and efficacy in real-world clinical settings.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit NUVB on AllInvestView.